Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Mallinckrodt PLC

www.mallinckrodt.com

Latest From Mallinckrodt PLC

Interview: Altan Eyes Opportunities In US Pain Market

The Irish specialty pharma has made its first filing in the US with an infusion of acetaminophen that Altan hopes will break the monopoly of Mallinckrodt's Ofirmev.

Neurology Generic Drugs

Opioid Makers May Have To Pay For Prevention Costs Of 'Man-Made Plague,' Judge Suggests

Bellwether trial set to begin in September after judge says cities may be able to recover damages for cost of governmental services that are the result of defendants' alleged conduct.
Legal Issues Drug Safety

Where Is OxyContin Abuse Deterrent Data? Purdue Has Sent Two Studies, But Wait Continues

US FDA expects to receive two more postmarket studies this year, but Purdue has not yet decided if it will resubmit a supplemental NDA. Consortium of 13 companies have completed six additional studies on extended-release opioids.

Post Market Regulation & Studies Drug Safety

House Oversight Drug Pricing Hearings Will Begin With Expert, Patient Witnesses

Manufacturers will avoid direct interrogation in first round, but Oversight Committee also seeking information from sponsors on reasons behind price increases. In US Senate, Susan Collins writes to HHS Secretary Alex Azar urging the department to move ahead with rebate reform.

Pricing Debate Legislation
See All

Company Information

Advertisement
Advertisement
UsernamePublicRestriction

Register